We look forward to welcoming you to the 8th annual E-Cigarette Summit US, which will take place in Washington D.C on May 14 2024.

It was lovely to come back to Washington D.C last year and see so many people again in person.  We were pleased to have a full house and also to welcome so many on-line with the hybrid model.  The feedback was extremely positive, and we will continue to offer this as an option for all future Summits.

We have now made the videos from the 2023 Summit open access and they  can be viewed either on the Agenda Page or by clicking HERE

We will be updating this site with the 2024 speakers and agenda in due course.  The current agenda and speakers showing are from the 2023 event.


To view the full agenda and confirmed speakers please click HERE.

The Opening Keynote will be delivered by Dr Brian King Director for the Center for Tobacco Products at the Food and Drug Administration (FDA).  With almost two decades of experience in translating scientific evidence to inform tobacco control policies, Dr King joined the FDA in July 22 and is charged with ensuring that the CTP accomplishes its public health goals as it implements the Family Smoking Prevention and Tobacco Control ACT.

In the Closing Keynote, Tom Glynn will moderate a dialogue with Cliff Douglas and Mitch Zeller on the potential “End State” for tobacco control efforts.  Rather than focusing on the pros or cons of various harm reduction approaches, Cliff and Mitch will describe the differences between potentially competing visions for what “success” looks like.

In 1962 and 1964 respectively,  the UK’s Royal College of Physicians and the US Surgeon General,  published 2 ground breaking reports, which for the first time directly linked cigarette smoking with lung cancer.  These landmark publications were the catalyst for the modern-day tobacco control movement which for 60 years has seen the public health and tobacco control communities align around a single common goal – to end the smoking epidemic.

The emergence of e-cigarettes and novel nicotine products has introduced the first challenge to the consensus that formed around smoking, forcing us to consider whether the ultimate public health goal remains the defeat of the cigarette and its toll of death and disease, even if that means accepting the continued use of nicotine in society.  In resolving this dilemma, public health bodies are tasked with balancing concerns about youth initiation (and the perennial distrust of industry motivation), with the opportunity to potentially prevent millions of premature deaths.

In 2023, smoking remains the single biggest cause of preventable death and disease in the developed world and with over 30 million Americans still smoking, the need for a comprehensive tobacco control/public health plan has never been more important. The E-Cigarette Summit has a single aim of facilitating respectful dialogue and thoughtful analysis of the latest evidence and an opportunity to explore how this should be interpreted to deliver the most effective public health and regulatory strategies.



Adjunct Lecturer, Stanford Prevention Research Center

Stanford University School of Medicine

Prof Thomas J. Glynn
Adjunct Lecturer, Stanford Prevention Research Center, Stanford University School of Medicine


Deborah Arnott

Chief Executive

Action on Smoking and Health (UK)

Alex Clark

Chief Executive Officer


Clive Bates


Counterfactual Consulting Ltd

Prof Matthew Carpenter

Professor & Co-leader of the Cancer Control Program of the Hollings Cancer Center

Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina

Associate Prof Abigail Friedman

Associate Professor

Dept of Health Policy & Management, Yale School of Public Health

Dr. Nancy A. Rigotti, MD

Professor of Medicine, Harvard Medical School

Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston

Tim Phillips

Managing Director


Kathleen Crosby

Director, Office of Health Communication & Education

FDA Center for Tobacco Products

Benjamin Apelberg, Ph.D

Deputy Director for Regulatory Science in the Office of Science

FDA’s Center for Tobacco Products (CTP)

Dr Brian King

Director, Center for Tobacco Products (CTP)

Food and Drug Administration (FDA)

Dr. Sonia Johnson

Director General of the Tobacco Control Directorate

Health Canada

Professor Ann McNeill

Professor of Tobacco Addiction

Institute of Psychiatry, Psychology & Neuroscience,, Kings College London

Prof David Levy

Professor of Oncology

Lombardl Comprehensive Cancer Center, Georgetown University

Dr Jamie Hartmann-Boyce

Associate Professor and Editor, Cochrane Tobacco Addiction Group

Nuffield Department of Primary Care Health Sciences, University of Oxford

Prof Jonathan Foulds

Professor Department of Public Health Sciences Division of Health Services and Behavioral Research

Penn State Center for Research on Tobacco and Health

Andy Hyland

Chair, Department of Health Behavior

Roswell Park Comprehensive Cancer Center

Prof Maciej L. Goniewicz

Professor of Oncology, Department of Health Behavior, Division of Cancer Prevention and Population Studies,

Roswell Park Comprehensive Cancer Center

Dr Ray Niaura

Professor of Social & Behavioural Health & Co-Director of the Tobacco Research Lab

School of Global Public Health, New York University

Prof Kenneth Warner

Professor Emeritus and Dean Emeritus

School of Public Health, University of Michigan

Cliff Douglas, JD

Director, Tobacco Research Network, Adjunct Professor, Department of Health Management and Policy

School of Public Health, University of Michigan

Prof Thomas J. Glynn, PhD

Adjunct Lecturer

Stanford Prevention Research Centre, Stanford University School of Medicine

Mitch Zeller J.D

Director (Retired) Center for Tobacco Products (CTP)

The Food & Drug Administration (FDA)

Prof Neal L. Benowitz MD

Professor of Medicine Emeritus (Active)

University of California, San Franciso

Prof Robin Mermelstein

Distinguished Professor of Psychology and IHRP Director

University of Illinois, Chicago

Prof Peter Hajek

Professor of Clinical Psychology & Director of the Tobacco Dependence Research Unit

Wolfson Institute of Public Health, Queen Mary University of London

Ben Youdan


Youdan Consulting - New Zealand


The E-Cigarette Summit provides an evidence based environment that encourages open and respectful dialogue on the key science and current public health topics. The format includes high level briefings from global experts followed by panel discussions and audience Q&A.

  • If vaping Is a gateway to cigarette smoking, what are the implications?
  • Past and future trends in nicotine-delivery product use
  • Effects of reduced-risk nicotine products on smoking prevalence and cigarette sales
  • Flavored nicotine product sales restrictions in the US: Policy variations and impacts
  • Are e-cigarettes less addictive than cigarettes – why does it matter?
  • E-Cigarettes and smoking cessation – understanding the data
  • Evidence, emotions and philosophy – why all are important in tobacco control policy
  • The key differences and similarities of vaporized cannabis versus nicotine
  • Risk perception of e-cigarettes and vaping – the role of health communication
  • Interactions between cannabis and nicotine use
  • Policy comparisons between the US, Canada, UK and New Zealand – Who is doing what and why.
  • What doctors say…and what patients hear – should e-cigarettes be recommended for smoking cessation?
  • What can we learn from historical events and US per-capita cigarette data from 1984 to present?
  • E-cigarettes and mental health disorders: Opportunity or concern?
  • What constitutes success?  A dialogue on the “end state”


The E-Cigarette Summit is particularly relevant to:

  • Regulators and policy advisors
  • Health providers and public health advocates
  • National, state and local legislators and their staffs
  • Public health professionals
  • Scientific/research community
  • Medical and health professionals
  • e-cigarette industry stakeholders


  • Regulators and policy advisors
  • Health providers and public health advocates
  • National, state and local legislators and their staffs
  • Public health professionals
  • Scientific/research community
  • Medical and health professionals
  • e-cigarette industry stakeholders